Prostate Cancer - Results from #22520

Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer - Abstract September 13, 2013

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer - Abstract September 13, 2013

Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer - Abstract September 12, 2013

Quality of prostate cancer care among rural men in the Veterans Health Administration - Abstract September 12, 2013

Oncologic outcomes following radical prostatectomy in the active surveillance era - Abstract September 12, 2013

Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berli - Abstract September 12, 2013

Re-implantation after insufficient primary 125-I permanent prostate brachytherapy - Abstract September 12, 2013

The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer - Abstract September 12, 2013

Proteomic serum profile of fatigued men receiving localized external beam radiation therapy for non-metastatic prostate cancer - Abstract September 12, 2013

Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey - Abstract September 12, 2013

Bone cancer pain: Causes, consequences, and therapeutic opportunities - Abstract September 12, 2013

Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases - Abstract September 12, 2013

Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer - Abstract September 11, 2013

Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer - Abstract September 11, 2013

The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer - Abstract September 11, 2013

Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis - Abstract September 11, 2013

Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty - Abstract September 11, 2013

Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: Initial single institution experience - Abstract September 11, 2013

Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: Implications for the use of newer isotopes - Abstract September 11, 2013

Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation - Abstract September 11, 2013

Page 1127 of 1447